Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland2Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
JAMA Intern Med. 2015 Oct;175(10):1642-9. doi: 10.1001/jamainternmed.2015.3931.
Prescription Drug Monitoring Program (PDMP) and pill mill laws are among the principal means states use to reduce prescription drug abuse and diversion, yet little high-quality evidence exists regarding their effect.
To quantify the effect of Florida's PDMP and pill mill laws on overall and high-risk opioid prescribing and use.
DESIGN, SETTING, AND PARTICIPANTS: We applied comparative interrupted time-series analyses to IMS Health LifeLink LRx data to characterize the effect of PDMP and pill mill law implementation on a closed cohort of prescribers, retail pharmacies, and patients from July 2010 through September 2012 in Florida (intervention state) compared with Georgia (control state). We conducted sensitivity analyses, including varying length of observation and modifying requirements for continuous observation of individuals throughout the study period.
Total opioid volume, mean morphine milligram equivalent (MME) per transaction, mean days' supply per transaction, and total number of opioid prescriptions dispensed. Analyses were conducted per prescriber and per patient, in aggregate and after stratifying by volume of baseline opioid prescribing for prescribers and use for patients.
From July 2010 through September 2012, a cohort of 2.6 million patients, 431,890 prescribers, and 2829 pharmacies was associated with approximately 480 million prescriptions in Florida and Georgia, 7.7% of which were for opioids. Total monthly opioid volume, MME per transaction, days' supply, and prescriptions dispensed were higher in Florida than Georgia before implementation. Florida's laws were associated with statistically significant declines in opioid volume (2.5 kg/mo, P<.05; equivalent to approximately 500,000 5-mg tablets of hydrocodone bitartrate per month) and MME per transaction (0.45 mg/mo, P<.05), without any change in days' supply. Twelve months after implementation, the policies were associated with approximately a 1.4% decrease in opioid prescriptions, 2.5% decrease in opioid volume, and 5.6% decrease in MME per transaction. Reductions were limited to prescribers and patients with the highest baseline opioid prescribing and use. Sensitivity analyses, varying time windows, and enrollment criteria supported the main results.
Florida's PDMP and pill mill laws were associated with modest decreases in opioid prescribing and use. Decreases were greatest among prescribers and patients with the highest baseline opioid prescribing and use.
处方药物监测计划(PDMP)和制毒药房法是各州用于减少处方药物滥用和转移的主要手段之一,但关于它们的效果,几乎没有高质量的证据。
量化佛罗里达州 PDMP 和制毒药房法对整体和高风险阿片类药物处方和使用的影响。
设计、环境和参与者:我们应用比较中断时间序列分析方法,对 IMS Health LifeLink LRx 数据进行分析,以描述 PDMP 和制毒药房法的实施对 2010 年 7 月至 2012 年 9 月期间佛罗里达州(干预州)和佐治亚州(对照州)一个封闭的开方医生、零售药房和患者队列的影响。我们进行了敏感性分析,包括改变观察时间长度和修改整个研究期间个体连续观察的要求。
总阿片类药物用量、每笔交易的平均吗啡毫克当量(MME)、每笔交易的平均供应天数和总阿片类药物处方数量。分析根据开方医生和患者进行,在综合分析的基础上,根据开方医生基线阿片类药物处方量和患者使用量进行分层分析。
在 2010 年 7 月至 2012 年 9 月期间,与佛罗里达州和佐治亚州大约 4.8 亿张处方相关的一个 260 万患者、431890 名开方医生和 2829 家药房的队列中,有 7.7%是阿片类药物处方。在实施之前,佛罗里达州的每月总阿片类药物用量、每笔交易的 MME、供应天数和处方数量均高于佐治亚州。佛罗里达州的法律与阿片类药物用量(2.5 公斤/月,P<.05;相当于每月大约 500000 片 5 毫克氢可酮酒石酸盐)和每笔交易的 MME(0.45 毫克/月,P<.05)的统计学显著下降有关,而供应天数没有变化。实施后 12 个月,这些政策与阿片类药物处方减少约 1.4%、阿片类药物用量减少 2.5%和 MME 每笔交易减少 5.6%有关。减少仅限于基线阿片类药物处方和使用量最高的开方医生和患者。敏感性分析、不同的时间窗口和登记标准支持主要结果。
佛罗里达州的 PDMP 和制毒药房法与阿片类药物处方和使用量的适度减少有关。减少幅度最大的是基线阿片类药物处方和使用量最高的开方医生和患者。